

TFW

1614

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the below date:

Date: October 31, 2006 Name: Sara E. Vessely

Signature: Sara E. Vessely

BRINKS
HOFER
GILSON
& LIONE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appln. of: Amadeo Parassenti

Appln. No.: 10/580,507

Filed: November 26, 2004

For: USE OF ISOGENIC DRUG-RESISTANT
CELL LINES TO DETERMINE THE
SEQUENCE OF CHEMOTHERAPEUTIC
DRUG TREATMENT

Examiner: Unknown

Art Unit: 1614

Conf. No. 2338

Attorney Docket No: 12332/006

MAIL STOP AMENDMENT
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL

Sir:

Attached is/are:

- ☒ Disclosure of Prior Art (2 pgs.); PTO-1449 (2 pgs.); Copies of References (13 documents)
☒ Return Receipt Postcard.

Fee calculation:

- ☒ No additional fee is required.
☐ Small Entity.
☐ An extension fee in an amount of \$_____ for a _____-month extension of time under 37 C.F.R. § 1.136(a).
☐ A petition or processing fee in an amount of \$_____ under 37 C.F.R. § 1.17(____).
☐ An additional filing fee has been calculated as shown below:

					Small Entity			Not a Small Entity	
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Add'l Fee	or	Rate	Add'l Fee
Total		Minus			x \$25=			x \$50=	
Indep.		Minus			x 100=			x \$200=	
First Presentation of Multiple Dep. Claim					+\$180=			+\$360=	
					Total	\$		Total	\$

Fee payment:


- ☐ A check in the amount of \$_____ is enclosed.
☐ Please charge Deposit Account No. 23-1925 in the amount of \$_____. A copy of this Transmittal is enclosed for this purpose.
☐ Payment by credit card in the amount of \$_____ (Form PTO-2038 is attached).

- ☒ The Director is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this paper (including any extension fee required to ensure that this paper is timely filed), or to credit any overpayment, to Deposit Account No. 23-1925. A copy of this Transmittal is enclosed for this purpose.

Date

10/31/06


Respectfully submitted,



A. James Richardson (Reg. No. 26,983)

Certificate Under 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with
with the United States Postal Service with sufficient postage as
first-class mail in an envelope addressed to: Commissioner for
Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on
October 31, 2006


Sara E. Vessely



PATENT
Our Case No. 12332/006

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re: patent application of)	
)	
Amadeo Parissenti)	Examiner: Unknown
)	
Serial No.: 10/580,507)	
)	Group Art Unit: 1614
Filed: November 26, 2004)	
)	Confirmation No.: 2338
For: USE OF ISOGENIC DRUG-RESISTANT)	
CELL LINES TO DETERMINE THE)	
SEQUENCE OF CHEMOTHERAPEUTIC)	
DRUG TREATMENT)	
)	

DISCLOSURE OF PRIOR ART UNDER 37 C.F.R. 1.56

MAIL STOP AMENDMENT
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313

Sir:

In connection with the examination of the above-identified application, the
applicant, through the subscribing attorney, hereby invites the Examiner's attention to the
enclosed list of prior art.

While the attached list of prior art is believed to include the closest prior art of which the applicant is presently aware, the applicant does not represent that any search for prior art has necessarily been made nor that no better prior art exists. All the listed prior art is in the English language and therefore no explanation of its relevance is believed to be necessary. The Examiner is requested to consider the listed prior art when evaluating the patentability of the invention claimed in the present application.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'A. James Richardson', with a stylized flourish at the end.

A. James Richardson
Reg. No. 26,983

BRINKS HOFER GILSON & LIONE
CUSTOMER NO. 27879
Telephone: (317) 636-0886
Fax: (317) 634-6701



FORM PTO-1449	APPLICATION NO. 10/580,507	ATTORNEY DOCKET NO. 12332/006
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE November 26, 2004	GROUP ART UNIT 1614
(use several sheets if necessary)	FIRST NAMED INVENTOR: Amadeo Parissenti	
	EXAMINER NAME: Unknown	

EXAMINER INITIALS	Cite No.	DOCUMENT NUMBER Number-Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where, Relevant Passages or Relevant Figures Appear
	A1	6,664,288 B1	12/16/2003	Pardee et al.	
	A2	6,875,745 B2	04/05/2005	Pardee et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER Number-Kind Code (if known)	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES OR NO
	A3	CA 2 369 303 A1	10/19/2000	Canada	A61K 31/35	

EXAMINER INITIAL	NON PATENT LITERATURE DOCUMENTS (Include name of author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.			T
	A4	Crown, John, Nonanthracycline Containing Docetaxel-Based Combinations in Metastatic Breast Cancer, The Oncologist 2001:6 (suppl 3): pp. 17-21, AlphaMed Press.		
	A5	L. Austin Doyle, et al., A Multidrug Resistance Transporter From Human MCF-7 Breast Cancer Cells, Prac. Natl. Acad. Sci., Vol. 95, pp. 15665-15670, December 1998.		
	A6	Douglas D. Ross, et al., Atypical Multidrug Resistance: Breast Cancer Resistance Protein Messenger RNA Expression in Mitochondria-Selected Cell Lines, Journal of the National Cancer Institute, Vol. 91, No. 5, March 3, 1999.		

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	SERIAL NO. Error! Reference source not found.	CASE NO. Error! Reference source not found.
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE Error! Reference source not found.	GROUP ART UNIT Error! Reference source not found.
(use several sheets if necessary)	APPLICANT(S): Error! Reference source not found.	

EXAMINER INITIAL	NON PATENT LITERATURE DOCUMENTS (Include name of author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.		T
	A7	Eswaran Devarajan, et al., Human Breast Cancer MCF-7 Cell Line Contains Inherently Drug-Resistant Subclones With Distinct Genotypic and Phenotypic Features, International Journal of Oncology 20: pp. 913-920, 2002.	
	A8	Erin L. Volk, et al., Methotrexate Cross-Resistance in a Mitoxantrone-selected Multidrug-Resistant MCF-7 Breast Cancer Cell Line Is Attributable to Enhanced Energy-Dependent Drug Efflux, Cancer Research 60: pp. 3514-3521, July 1, 2000.	
	A9	Thomas Litman, et al., The Multidrug-Resistant Phenotype Associated with Overexpression of the New ABC Half-Transporter, MXR (ABCG2), Journal of Cell Science 113, pp. 2011-2021, 2000, Great Britain.	
	A10	Gen Sheng Wu and Zhenhua Ding, Caspase 9 is Required for p53-Dependent Apoptosis and Chemosensitivity in a Human Ovarian Cancer Cell Line, Oncogene 21, pp. 1-8, 2002.	
	A11	Baoqing Guo, et al., Potent Killing of Paclitaxel and Doxorubicin-Resistant Breast Cancer Cells By Calphostin C Accompanied by Cytoplasmic Vacuolization, Breast Cancer Research and Treatment 82: pp. 125-141, 2003, Netherlands.	
	A12	Soo-Jung Park, et al., A P-glycoprotein and MRP1-Independent Doxorubicin-Resistant Variant of the MCF-7 Breast Cancer Cell Line with Defects in Capase-6, -7, -8, -9 and -10 Activation Pathways, Anticancer Research 24: pp. 123-132, 2004.	
	A13	Kostas V. Floros, et al., mRNA Expression Analysis of a Variety of Apoptosis-Related Genes, Including the Novel Gene of the BCL2-Family, BCL2L12, in HL-60 Leukemia Cells After Treatment with Carboplatin and Doxorubicin, Biol. Chem., Vol. 385, pp. 1099-1103, November 2004, Berlin, NY.	
	A14	Ching-Huang Wu, et al., β 2-Microglobulin Induces Apoptosis in HL-60 Human Leukemia Cell Line and Its Multidrug Resistant Variants Overexpressing MRP1 but Lacking Bax or Overexpressing P-glycoprotein, Oncogene 20, pp. 7006-7020, 2001.	
	A15	Tamara Minko, et al., Preliminary Evaluation of Caspases-Dependent Apoptosis signaling Pathways of Free and HPMA Copolymer-Bound Doxorubicin in Human Ovarian Carcinoma Cells, Journal of Controlled Release 71, pp. 227-237, 2001.	

NOTE: For "T" – please place an "X" if an English translation is being provided to the Patent Office.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.